Soliton Appoints Mary Stoll as Senior Director of Clinical Development

HOUSTON, Dec. 10, 2019 /PRNewswire/ --Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the appointment of Mary Stoll as Senior Director of Clinical Development.